EVALUATION OF INNOVATIVE CO-PROCESSED ADDITIVE FOR DIRECT COMPRESSION TABLETS USING ATORVASTATIN AND DIAZEPAM AS MODEL DRUGS
Objective: The aim of the present study is to prepare and evaluate a co-processed excipient from commercially available Avecil PH102 and silicon dioxide colloidal (SDC) using direct compression technique for preparation of tablets.
Methods: The effect of the ratio of the two components on the properties of the prepared co-processed excipient has been investigated. In addition, it was evaluated for flowability, compressibility, and compatibility utilizing Fourier transforms Infrared (FTIR) and Differential scanning calorimetry (DSC) analysis. Tablets were produced by direct compression utilizing the co-processed additive with diazepam or atorvastatin calcium as model drugs in addition to magnesium stearate and talc as a lubricant. The addition of super disintegrant croscarmellose sodium or tablets preparation by wet granulation was utilized for comparison regarding the properties of prepared tablets. The prepared tablets were characterized for the drug content, hardness, friability, disintegration, dissolution, and stability.
Results: Optimal physicochemical properties of the excipient from a manufacturing perspective were obtained using a co-processed Avecil PH102-with SDC (2% w/w) to get a mixture. The FTIR and DSC analysis showed no chemical interaction. The properties of tablets made using co-processed excipient showed good hardness, friability, acceptable tablet disintegration time, dissolution rate, and stability comparable to that obtained by the multistep method of wet granulation. Although the addition of super disintegrant more shorten the disintegration time but the obtained value without croscarmellose sodium is still satisfied the requirement.
Conclusion: The Avecil PH102-SDC co-processed excipient produced was found to be promising as a valuable industrial, pharmaceutical excipient for the production of compressed tablets with good physical properties and fast dissolution.
2. Rasenack N, Muller BW. Crystal habit and tableting behaviour. Int J Pharm 2002;244:45-57.
3. Sam AP, Fokkens JG. Drug delivery system: adding therapeutic and economic value to pharmacotherapy. Pharm Technol Eur 1997;9:58-66.
4. Russell R. Synthetic excipients challenge all-natural organicsâ€”offer advantages/Challenges to developers and formulators. Pharm Technol 2004;27:38â€“50.
5. Reimerdes. The Near Future of Tablet Excipients.â€ Manuf Chem 1993;64:14â€“5.
6. Reimerdes D, Aufmuth KP. Tabletting with Co-processed lactose-cellulose excipients. Manuf Chem 1992;63:21-4.
7. British Pharmacopoeia Commission. Powder flow. London, UK: British Pharmacopoeia Commission; 2007.
8. Hisakadzu S, Yunxia B. Preparation, evaluation and optimization of rapidly disintegrating tablets. Powder Technol 2002;122:188-98.
9. Ahmed S, Nazmi M, Hasan I, Sultana S, Haldar S, Reza MS. Fexofenadine HCl immediate release tablets: in vitro characterization and evaluation of excipients. Bangladesh Pharm J 2013;16:1-9.
10. Venkata raveendra babu vemula, Pankaj kumar Sharma. Analytical method development and validation for simultaneous estimation of imipramine and diazepam in tablet dosage form by RP-HPLC. Int J Pharm Pharm Sci 2013;5:249-53.
11. Kahtan J Hasson. Enhancement of atorvastatin tablet dissolution using the acid medium. Iraqi J Pharm Sci 2010;19:82-5.
12. Marshall K, Lachman N, Liberman HA. The theory and practice of industrial pharmacy. 3rd Ed. Varghese Publishing House, Mumbai; 1987. p. 66-9.
13. British Pharmacopoeia. Published on the recommendation of the Commission, Pursuant to the Medicines Act 1968, The Stationery Office, London; 2009. p. 6582-3.
14. The United States Pharmacopoeia 26. United States Pharmacopeial Convention, inc., Rockville; 2003. p. 587-90.
15. Ajay Sabhash Chougule. Formulation development techniques of Co-processed excipients. J Adv Pharm Sci 2012;2:231â€“49.
16. Chella Naveen, Nalini Shastri, Rama Rao Tadikonda. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharm Sin B 2012;2:502-8.
17. Fahmy RH, Kassem MA. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2008;69:993-1003.
18. Sabale PM, Grampurohit ND, Gaikawad DD. Liquisolid technique for enhancement of dissolution properties of fenofibrate. Int J Pharm Sci Res 2012;3:1481-6.
19. Sanjay SP, Natvarlal MP. Development of directly compressible co-processed excipient for dispersible tablets using 32 full factorial design. Int J Pharm Pharm Sci 2009;1:125-48.